$0.52
5.09% yesterday
Nasdaq, Aug 12, 10:10 pm CET
ISIN
US2546685023
Symbol
WINT

Windtree Therapeutics Inc Stock price

$0.52
-0.27 34.43% 1M
-7.99 93.91% 6M
-16.95 97.03% YTD
-589.48 99.91% 1Y
-17,846.63 100.00% 3Y
-353,346.14 100.00% 5Y
-54,026,433.05 100.00% 10Y
-11,929,090,908.57 100.00% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
-0.03 5.09%
ISIN
US2546685023
Symbol
WINT
Industry

Key metrics

Basic
Market capitalization
$15.3m
Enterprise Value
$14.6m
Net debt
positive
Cash
$1.2m
Shares outstanding
3.6m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.4
Financial Health
Equity Ratio
47.3%
Return on Equity
-
ROCE
-121.8%
ROIC
-111.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-24.6m | -
EBIT
$-24.7m | $-19.4m
Net Income
$-20.8m | $-7.8m
Free Cash Flow
$-14.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-35.6% | -
EBIT
-35.5% | -
Net Income
-248.2% | -
Free Cash Flow
-7.1%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-19.1
FCF per Share
$-4.2
Short interest
22.5%
Employees
14
Rev per Employee
-
Show more

Is Windtree Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Windtree Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Windtree Therapeutics Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Windtree Therapeutics Inc forecast:

Hold
50%
Sell
50%

Financial data from Windtree Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.41 8.41
7% 7%
-
- Research and Development Expense 16 16
77% 77%
-
-25 -25
36% 36%
-
- Depreciation and Amortization 0.08 0.08
0% 0%
-
EBIT (Operating Income) EBIT -25 -25
35% 35%
-
Net Profit -21 -21
248% 248%
-

In millions USD.

Don't miss a Thing! We will send you all news about Windtree Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Windtree Therapeutics Inc Stock News

Neutral
GlobeNewsWire
one day ago
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C
Neutral
GlobeNewsWire
14 days ago
Investors choose to redeem or convert the majority of Series C and Series D Preferred 99% of outstanding preferred series C shares are redeemed or converted and preferred series D reduced 68.5% in outstanding shares BNB coin has appreciated over 17% since Windtree announced crypto treasury agreement with Build and Build Corp displaying the underlying demand for the coin globally WARRINGTON, Pa....
Neutral
GlobeNewsWire
19 days ago
Up to $700 Million Committed to BNB Acquisitions, Reinforcing Innovative Crypto Treasury Strategy Ninety Nine Percent of the proceeds from both issuances to be used to buy BNB WARRINGTON, Pa., July 24, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company diversifying its portfolio through strategic initiatives, today announ...
More Windtree Therapeutics Inc News

Company Profile

Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.

Head office United States
CEO Jed Latkin
Employees 14
Founded 1992
Website windtreetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today